Voyager's Parkinson's Gene Therapy Poised For Pivotal Trial Exploration

The Cambridge, Mass.-based biotech announced updated data from a Phase Ib trial of a gene therapy for Parkinson's disease, showing improvements in motor function and less time with dyskinesia.